Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA offers researchers new guidance to help keep trials on track.
Approval was based on a study showing combination treatment reduced disease progression or death by 40%.
The efficacy of Nerlynx with capecitabine was investigated in a randomized, multicenter, open-label clinical trial in 621 people.
The agency reviewed a decade of animal and epidemiological studies in search of such evidence.
Potential risk of cancer outweighs the benefits
The National Cancer Institute stands to lose more than $500 million, and cancer prevention programs are at risk.
Epithelioid sarcoma is a rare sub-type of soft tissue sarcoma that often occurs in young adults.
New research adds to our understanding of sunscreens.
A clinical trial shows a possible increased risk of cancer and the FDA is continuing to evaluate the results.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
The drug was previously approved for castration-resistant prostate cancer.
New site-agnostic therapies highlight the importance of genetic testing.
Oncologist wins Senate backing by a vote of 72 to 18.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
A public workshop organized by the FDA and MRA
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.